The availability of long-acting injectable (LAI) antipsychotics for the treatment of
schizophrenia provides clinicians with options that deliver continuous drug exposure and …

Long-acting formulations are designed to reduce dosing frequency and simplify dosing
schedules by providing an extended duration of action. One approach to obtain long-acting …

Abstract Purpose of Review Over the last ten years, the treatment of psychosis has seen a
near explosion of creative development in both novel agents and new delivery modalities …

Rationale While one of the basic axioms of pharmacology postulates that there is a
relationship between the concentration and effects of a drug, the value of measuring blood …

Medication nonadherence in schizophrenia can have serious implications including
relapses and hospitalization. Long-acting injectable (LAI) antipsychotics require fewer …

Formulating aqueous suspensions is an attractive strategy to incorporate poorly water-
soluble drugs, where the drug release can be tailored to maintain desired release profiles of …

Schizophrenia is a chronic medical condition with periods of remission and relapses over a
patient's lifetime. Antipsychotic medications represent the mainstay of treatment for this …

Innovations in the field of long-acting injectable drug development are increasingly being
reported. More advanced in vitro and in vivo characterization can improve our …

There are now 9 available FDA-approved second-generation long-acting injectable
antipsychotics including aripiprazole (3), olanzapine (1), paliperidone (3), and risperidone …

Most patients with schizophrenia need life-long treatment. There is therefore a continued
need for effective and tolerable treatment options. A 2-monthly LAI formulation of …